Edaravone Brand Name– Radicava
What is Edaravone
Edaravone is an intravenous antioxidant approved for the treatment of amyotrophic lateral sclerosis (ALS).
Edaravone is not curative; however, it may slow the decline of functional abilities that occurs with ALS.
In a 6-month, randomized, placebo-controlled, double-blind clinical trial, edaravone was associated with a significantly smaller decline in Amyotrophic Lateral Sclerosis Functional Rating Scale – Revised (ALSFRS-R) mean scores from baseline compared to placebo (-5.01 +/- 0.64 vs. -7.5 +/- 0.66; p = 0.0013). Higher ALSFRS-R scores represent greater functional ability.
Hypersensitivity reactions, including serious reactions such as anaphylaxis, have been reported with edaravone use
Indications
- amyotrophic lateral sclerosis (ALS)
For the treatment of amyotrophic lateral sclerosis (ALS)
Side Effects
- anaphylactoid reactions
- dyspnea
- erythema multiforme
- glycosuria
- headache
- hypotension
- hypoxia
- infection
- urticaria
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- asthma
- breast-feeding
- pregnancy
- sulfite hypersensitivity
Interactions
There are no drug interactions associated with Edaravone products.
